Your browser is no longer supported. Please, upgrade your browser.
Settings
SAGE Sage Therapeutics, Inc. daily Stock Chart
SAGE [NASD]
Sage Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.40 Insider Own3.52% Shs Outstand47.31M Perf Week13.17%
Market Cap6.42B Forward P/E- EPS next Y-10.85 Insider Trans0.00% Shs Float45.24M Perf Month32.95%
Income-283.90M PEG- EPS next Q-2.91 Inst Own- Short Float7.78% Perf Quarter8.64%
Sales90.00M P/S71.28 EPS this Y-49.30% Inst Trans0.13% Short Ratio6.00 Perf Half Y-19.49%
Book/sh21.16 P/B6.41 EPS next Y-43.30% ROA-29.80% Target Price201.38 Perf Year-22.89%
Cash/sh21.59 P/C6.28 EPS next 5Y13.10% ROE-31.50% 52W Range79.88 - 195.97 Perf YTD41.56%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-30.81% Beta2.74
Dividend %- Quick Ratio19.10 Sales past 5Y- Gross Margin- 52W Low69.75% ATR9.70
Employees257 Current Ratio19.10 Sales Q/Q- Oper. Margin- RSI (14)65.59 Volatility4.96% 7.94%
OptionableYes Debt/Eq0.00 EPS Q/Q-33.80% Profit Margin- Rel Volume1.18 Prev Close131.94
ShortableYes LT Debt/Eq0.00 EarningsFeb 05 BMO Payout- Avg Volume586.71K Price135.60
Recom1.60 SMA2030.41% SMA5022.98% SMA200-3.84% Volume692,131 Change2.77%
Dec-14-18Initiated Wolfe Research Outperform
Oct-11-18Initiated Oppenheimer Outperform $170
Aug-07-18Reiterated Stifel Buy $198 → $239
Aug-06-18Initiated Piper Jaffray Overweight $206
Jun-06-18Initiated Ladenburg Thalmann Buy $230
Mar-26-18Resumed Canaccord Genuity Buy $210
Feb-26-18Initiated Morgan Stanley Overweight
Dec-08-17Reiterated Needham Buy $100 → $193
Dec-08-17Reiterated Canaccord Genuity Buy $140 → $191
Dec-07-17Reiterated Chardan Capital Markets Buy $140 → $225
Nov-10-17Upgrade Chardan Capital Markets Neutral → Buy $60 → $140
Nov-10-17Reiterated Needham Buy $86 → $100
Oct-06-17Resumed Goldman Buy $87
Sep-15-17Initiated RBC Capital Mkts Outperform $117
Sep-13-17Reiterated Needham Buy $95 → $86
Aug-09-17Resumed Stifel Buy $104
May-16-17Initiated Needham Buy $82
May-12-17Initiated BofA/Merrill Buy $85
Feb-22-17Downgrade H.C. Wainwright Buy → Neutral $56 → $76
Feb-14-17Upgrade Chardan Capital Markets Sell → Neutral $60
Jan-16-19 04:18PM  Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It Investor's Business Daily
08:05AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics ACCESSWIRE
Jan-15-19 08:00PM  3 Small-Cap Stocks With Big-Cap Potential Motley Fool
04:18PM  Here's How The Government Shutdown Will Affect These Medical Stocks Investor's Business Daily
Jan-11-19 07:46AM  The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference Motley Fool
Jan-10-19 03:23PM  3 Biggest Stories at the J.P. Morgan Healthcare Conference This Year Motley Fool +5.34%
Jan-09-19 03:07PM  Eyeing FDA approval, Sage lays out strategy for dual postpartum depression drugs American City Business Journals -7.40%
09:33AM  Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus Zacks
Jan-08-19 12:38PM  Here's Why Axsome Therapeutics Has Been a Rocket Ship This Week Motley Fool -6.99%
Jan-07-19 06:49PM  Biotech Stocks Post Double-Digit Gains in Monday Surge TheStreet.com +42.68%
04:56PM  What Happened in the Stock Market Today Motley Fool
01:27PM  Sage Therapeutics's stock shoots higher after postpartum depression treatment's positive trial results MarketWatch
11:45AM  Why Sage Therapeutics Is Skyrocketing Today Motley Fool
10:40AM  SAGE Therapeutics Soars on Promising Postpartum Drug-Trial Results TheStreet.com
07:35AM  Report: Developing Opportunities within General Mills, Philip Morris International, Sage Therapeutics, CNA Financial, Hess, and AutoNation Future Expectations, Projections Moving into 2019 GlobeNewswire
07:00AM  Sage Therapeutics to Provide Update on Key 2019 Initiatives at J.P. Morgan Healthcare Conference Business Wire
06:50AM  Today's Research Reports on Trending Tickers: Amarin Corporation and Sage Therapeutics ACCESSWIRE
06:31AM  Pill for postpartum depression by Cambridge's Sage succeeds in late-stage trial American City Business Journals
06:00AM  Sage's oral postpartum depression treatment succeeds in late-stage study Reuters
06:00AM  Sage Therapeutics Announces SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression Business Wire
Jan-04-19 06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire +9.16%
Jan-03-19 09:16AM  Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options Zacks
Dec-27-18 06:30AM  Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 Business Wire
Dec-24-18 01:13PM  Biotech Buying Spree: Why These 3 Stocks Could Get Deals In 2019 Investor's Business Daily
Dec-20-18 01:08PM  DAFNA Capital Management Return, AUM and Holdings Insider Monkey -8.86%
09:46AM  Has Sage Therapeutics, Inc. (NASDAQ:SAGE) Got Enough Cash? Simply Wall St.
Dec-14-18 07:00AM  Today's Research Reports on Trending Tickers: Sage Therapeutics and Altimmune ACCESSWIRE
Dec-12-18 04:12PM  Here's Why Marinus Pharmaceuticals Is Sinking Today Motley Fool
Dec-10-18 03:56AM  Hedge Funds Are Selling SAGE Therapeutics Inc (SAGE) Insider Monkey
Dec-05-18 06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-30-18 06:55AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sage Therapeutics ACCESSWIRE
Nov-29-18 07:45AM  New Research: Key Drivers of Growth for Upland Software, VICI Properties, Sage Therapeutics, Jack Henry & Associates, T2 Biosystems, and Tata Motors Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Nov-26-18 07:00AM  Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Sage Therapeutics ACCESSWIRE
Nov-21-18 06:30AM  Sage Therapeutics to Present at Piper Jaffray 30th Annual Healthcare Conference Business Wire
Nov-20-18 07:30AM  Sage Therapeutics Receives Notification of PDUFA Extension for ZULRESSO (brexanolone) Injection Business Wire
Nov-17-18 03:53PM  Edited Transcript of SAGE earnings conference call or presentation 6-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-16-18 07:00AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Sage Therapeutics ACCESSWIRE
Nov-12-18 05:54PM  Stocks making the biggest moves after hours: PG&E, Eventbrite and more CNBC -7.26%
Nov-07-18 04:01PM  Sage Therapeutics to Present at Stifel 2018 Healthcare Conference Business Wire
Nov-06-18 06:30AM  Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress Business Wire
Nov-05-18 07:00AM  Todays Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sage Therapeutics ACCESSWIRE -8.28%
06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-02-18 04:53PM  FDA panel recommends Sage's postpartum depression treatment Reuters
04:45PM  Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO (brexanolone) Injection for Treatment of Postpartum Depression Business Wire
03:03PM  FDA committee recommends Sage's postpartum depression drug American City Business Journals
07:09AM  Sage Therapeutics shares halted ahead of regulatory meeting on post-partum treatment MarketWatch
07:00AM  Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss ZULRESSO (brexanolone) Injection for the Treatment of Postpartum Depression Business Wire
Oct-31-18 08:00AM  Today's Research Reports on Trending Tickers: Exelixis and Sage Therapeutics ACCESSWIRE +6.15%
Oct-29-18 01:58PM  FDA set to review new drugs aimed at fighting depression CNBC Videos
Oct-26-18 11:18AM  Sage Therapeutics Turned Down - Don't Rush to Be a Buyer TheStreet.com
Oct-25-18 06:50PM  Cramer's lightning round: 'Take the money and run' with takeover stock Mazor Robotics CNBC +5.14%
Oct-24-18 08:00AM  Today's Research Reports on Trending Tickers: Sage Therapeutics and Ionis Pharmaceuticals ACCESSWIRE -7.32%
Oct-23-18 06:30AM  Sage Therapeutics to Report Third Quarter 2018 Financial Results on Tuesday, November 6, 2018 Business Wire
Oct-19-18 07:55AM  Detailed Research: Economic Perspectives on W.W. Grainger, Jabil, Grand Canyon Education, Sage Therapeutics, H. B. Fuller, and Jazz Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire
Sep-06-18 04:05PM  Sage Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference Business Wire
06:30AM  Sage Therapeutics Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-04-18 04:22PM  This Biotech's Drug Had No 'Red Flags' In Study Will FDA Panel Agree? Investor's Business Daily
Aug-31-18 06:40PM  Sage Therapeutics Announces The Lancet Publishes Integrated Data from Pivotal Trials for Brexanolone Injection in Postpartum Depression Business Wire
Aug-22-18 08:00AM  Today's Research Reports on Trending Tickers: Sage Therapeutics and CEL-SCI ACCESSWIRE
03:55AM  Edited Transcript of SAGE earnings conference call or presentation 7-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-13-18 10:16AM  Cambridge biotech Sage to open postpartum depression support center in North Carolina American City Business Journals
07:00AM  Sage Therapeutics targets Triangle for national postpartum depression support center American City Business Journals
Aug-07-18 06:30AM  Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress Business Wire
06:00AM  SAGE Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-18 06:30AM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Aug-01-18 06:30AM  Sage Therapeutics to Present at Canaccord 38th Annual Growth Conference Business Wire
Jul-24-18 06:30AM  Sage Therapeutics to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018 Business Wire
Jul-23-18 08:57AM  Amazon fuels T. Rowe Price U.S. mutual funds past the S&P 500 American City Business Journals
Jul-18-18 05:03PM  How to build a winning stock portfolio, and seven stocks to get you started MarketWatch
Jul-12-18 07:00PM  Cramer Remix: Investors can't see the reality of this market CNBC
06:56PM  Depression should be treated like a broken leg or a seizu... CNBC Videos
Jul-08-18 09:30AM  3 Top Biotech Stocks to Buy for the 2nd Half of 2018 Motley Fool
Jul-06-18 07:45AM  Complimentary Technical Snapshots on Verastem and Three More Biotech Stocks ACCESSWIRE
Jul-05-18 04:01PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jun-27-18 08:00AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics ACCESSWIRE
Jun-25-18 07:35AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sage Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Jun-21-18 08:00AM  Trending: Technology Sector Surges to Record Highs Despite Trade Jitters ETF Database
Jun-14-18 12:33PM  Why Biotech Stocks May Reach New Highs Investopedia
10:09AM  Sage shares drop 3% after $90 mln Shionogi deal for key drug MarketWatch
Jun-13-18 09:33PM  Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea Business Wire
04:40PM  Biotech Stock Loses Steam, But Analysts Still Bullish On Depression Drug Investor's Business Daily
10:07AM  Company News For Jun 13, 2018 Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Sage Therapeutics and Galmed Pharmaceuticals ACCESSWIRE
Jun-12-18 05:26PM  Here's Why Sage Therapeutics Rose as Much as 20.3% Today Motley Fool +19.62%
04:36PM  Is Sage Therapeutics Incs (NASDAQ:SAGE) Liquidity Good Enough? Simply Wall St.
04:32PM  Why Tesla, Sage Therapeutics, and Lands' End Jumped Today Motley Fool
04:15PM  Why This Biotech Company Is Bounding Closer To A Breakout Investor's Business Daily
01:47PM  Episodic drugs provide hope for depression sufferers CNBC Videos
11:10AM  Sage Therapeutics Rises After Depression Study Moves to Fast Lane Bloomberg
09:29AM  Sage shares surge 15% after FDA OKs expedited depression drug development CNBC
08:43AM  Sage shares surge 4.5% on plan to expedite drug development for two types of depression MarketWatch
07:55AM  Market Trends Toward New Normal in Cheniere Energy Partners, LP, UnitedHealth Group, Anthem, Sage Therapeutics, Harris, and A-Mark Precious Metals Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
06:30AM  Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting Business Wire
Jun-08-18 07:00AM  Sage Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference Business Wire
Jun-06-18 03:04PM  Analyst: Sage Therapeutics Holds A Breakthrough In Depression Treatment Benzinga
07:25AM  Sangamo Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space ACCESSWIRE
Jun-04-18 04:05PM  Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jun-01-18 07:35AM  Blog Exposure - FDA Approved Sage Therapeutics' NDA Filing for the Treatment of Postpartum Depression ACCESSWIRE
May-30-18 07:00AM  Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression Business Wire
May-24-18 11:34AM  Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today Motley Fool
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which has completed Phase II clinical trials for the treatment of PPD, major depressive disorders, bipolar depression, Parkinson's disease, and sleep disorders; and SAGE-718, an oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of depression, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, Huntington's disease, and neuropathic pain. In addition, its product pipeline comprises SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and product pipeline that are in preclinical stage includes SAGE-689 and SAGE-105 novel GABAA receptor modulators. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JONAS JEFFREY MPresident & CEOJan 09Option Exercise0.4510,0004,50062,115Jan 10 05:16 PM
IGUCHI KIMICFO & TreasurerJun 19Option Exercise0.4580036026,826Jun 20 04:07 PM
FRATES JAMES MDirectorMay 08Option Exercise8.927,00062,44012,000May 08 04:51 PM
FRATES JAMES MDirectorMay 08Sale154.007,0001,078,0005,000May 08 04:51 PM
IGUCHI KIMICFO & TreasurerApr 25Sale140.7511,0181,550,81038,345Apr 25 05:44 PM
IGUCHI KIMICFO & TreasurerApr 24Sale142.845,000714,18549,363Apr 25 05:44 PM
IGUCHI KIMICFO & TreasurerApr 23Sale144.4812,1351,753,30254,363Apr 25 05:44 PM
STARR KEVIN PDirectorApr 18Sale168.2824,0004,038,650302,817Apr 19 04:35 PM
STARR KEVIN PDirectorApr 17Sale169.2535,0005,923,600326,817Apr 19 04:35 PM
PAUL STEVEN MDirectorMar 06Sale172.0058,1399,999,908632,712Mar 08 04:02 PM